Real-World Outcomes of Hypomethylating Agents and Venetoclax Combination Therapy in AML and Myelodysplastic Syndrome in Pakistan
Effective AML combination therapy works similarly well in resource-limited countries as wealthy ones, demonstrating that this treatment approach can help patients globally despite care gaps.
HMA+venetoclax combination remains effective in a resource-limited LMIC oncology setting with outcomes comparable to published data from high-income settings, despite fewer patients proceeding to transplant. This study underscores the global equity gap in AML care and highlights febrile neutropenia management and EOT response as key clinical determinants.
What the study was
- Study design
- Retrospective single-center cohort study
- Population
- AML (n=54) and MDS (n=42) patients receiving HMA+VEN in Pakistan (LMIC setting)
- Sample size
- 96
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- JCO Global Oncology
Why it surfaced
Important LMIC real-world data on standard-of-care AML regimen; addresses global equity gap; n=96 is reasonable for this setting.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.